invasive meningococcal disease
Vaccines · 2018–2020
4decisions
4medicines
2carried consumer input
3individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine Prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W-135, and Y in children aged 12 months, adolescents aged… | Nov 2020 | Recommended | none received |
| meningococcal (groups A, C, W-135 and Y) oligosaccharide CRM197 conjugate vaccine Prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W-135 and Y in adolescents aged approximately 15 years… | Jul 2018 | Recommended with restriction | 1 individuals Meningitis Centre Australia |
| meningococcal polysaccharide conjugate vaccine serogroups A, C, W-135 and Y Prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W, and Y in infants aged 12 months. | Mar 2018 | Recommended | 2 individuals |
| meningococcal polysaccharide conjugate vaccine serogroups A, C, W-135 and Y (MenACWY-TT) Prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W-135 and Y in adolescents aged 14-16 years (Year 10… | Mar 2018 | Recommended with restriction | none received |
Who spoke
Meningitis Centre Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.